Urology — Certified
(314)362-8209
University of Texas School of Medicine, 1982
Research Fellow, University of Texas Medical School at Houston, 1979-1979
Intern in Surgery, Department of Surgery, Washington University School of Medicine, 1982-1983
Resident in Surgery, Department of Surgery, Washington University School of Medicine, 1983-1984
Resident in Surgery Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, 1984-1987
National Kidney Foundation Research Fellow, Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, 1985-1986
Chief Resident in Surgery, Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, 1987-1988
AFUD Scholar, Clinical Instructor, Division of Urologic Surgery, Washington University School of Medicine, 1988-1990
St. Louis VA Medical Center - John Cochran Division
915 North Grand Blvd.
Saint Louis, MO 63106
Center for Advanced Medicine
Urologic Surgery Center
4921 Parkview Place, Suite C, Floor 11
St. Louis, MO 63110
(314)362-8209
John Cochran VA Hospital
Barnes-Jewish Hospital
Barnes-Jewish West County Hospital
Current Research Projects:
Chemotherapy After Prostatectomy for High-Risk Prostatic Cancer. This VA Cooperative Study is a multicenter randomized trial involving use of Docetaxel and Prednisone versus standard of care for patients with adverse pathologic findings after radical prostatectomy.
Bladder Tumor Registry. This is a longitudinal, observational study of subjects diagnosed with bladder cancer in whom pathological features of bladder cancer are being correlated with clinical outcomes to therapy.
Vollmer RT, Hudson MA, Humphrey PA, Swanson PE, Wick MR. Prediction of bladder tumor invasiveness using a panel of immunohistochemical markers. Cancer. 1998;82:715-723.
Rabinowitz R, Smith DS, Tiemann DD, Hudson MA. Urinary interleukin-8/creatinine level as predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients. Journal of Urology. 1997;158:1722-1728.
Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, Jarowenko MV, Schellhammer PF, Schervish ED, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA, Brunelle SL. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 1997;50:349-353.
Kawakita M, Rao GS, Ritchey JK, Ornstein DK, Hudson MA, Tartaglia J, Paolette E and Ratliff TL. Effect of Carnarypox (ALVAC) virus-mediated cytokine gene expression on prostate tumor growth. Journal of the National Cancer Institute. 1997;89:408-409.
Hudson MA, McReynolds LM. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. Journal of the National Cancer Institute. 1997;89:708-717.
Ratliff TL, Hudson MA. BCG treatment: Current status. ACTA Urologica Belgia. 1996;64(2):25.
Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996;48:47-56.
Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, Koch MO, Schellhammer PF. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996;48:28-32.
Dalkin BL, Ahmann FR, Kopp JB, Catalona WJ, Ratliff TL, Hudson MA, Richie JP, Scardino PT, Flanigan RC, deKernion JB. Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma. British Journal of Urology. 1995;76(3):346-350.
Koiso K, Shipley W. Keuppens F, Baert L, Hall R, Hudson MA, Khoury S, Kubota Y, Kubota Y van Poppel H. The status of bladder-preserving therapeutic strategies in the management of patients with muscle-invasive bladder cancer. International Journal of Urology. 1995;2(suppl 2):49-57.
Sarosdy MF, DeVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. Journal of Urology. 1995;154:379-384.
Hudson MA, Ratliff TL, Failure of intravesical interferon alfa-2b for the treatment of patients with superficial bladder cancer previously failing intravesical BCG therapy. Urologic Oncology. 1995;1:115-118.
Hudson MA, Herr HW. Carcinoma in situ of the bladder. Journal of Urology. 1995;153:564-572.
Shenoy S, Hovsepian D, Brennan CD, Hudson MA, Howard TK, Flye MWL. Anomalous ureteral insertion in VATER syndrome complicating renal transplantation. Clinical Transplant. 1995;9:1-4.
Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumor-free response for intravesical BCG therapy. Journal of Urology. 1994;152:367-373.
Pub Med page for M'Liss A. Hudson, M.D.
Tsujii H, Gospodarowicz MK, Fujita K, Shimazaki J, Mitsuhashi N, Hudson MA, Bolla M, Fossa SD, Roberts JT. The place of radiotherapy for localized invasive bladder cancer. In: Proceedings of the Fifth International Consensus Conference on Bladder Cancer, Tokyo, Japan, 1997.
Hudson MA. New intravesical therapies in the treatment of superficial bladder cancer. In: Advances in Urology, Vol. 10, 1996.
Hudson MA. Screening for Prostate Cancer. AUA Update Series.
Hudson MA, Gerber AJ, Ratliff TL. Management of Superficial Bladder Cancer Ta/T1/Tis: Immunotherapy. In: Vogelganz NJ, Scardino PT, Shipley WU, Coffey DS. (eds.) Comprehensive Textbook of Genitourinary Oncology. Williams and Wilkins, 1996: 427-435.
Hudson MA, Catalona WJ. Transitional Cell Carcinoma of the Bladder, Upper Urinary Tract and Prostate. In: Gillenwater JY, Grayhack JT, Howards SS and Duckett JW. (eds.) Adult and Pediatric Urology. St. Louis: Mosby-Year Book, Inc.; 1996:1379-1464.
Hudson MA. Transurethral Resection of Bladder tumors. In: Marshall FF. (ed.) Textbook of Operative Urology. Philadelphia: WB Saunders Company, 1996, pp14-25.
Hudson MA, Bahnson RR, Catalona WJ. Clinical Use of Prostate-Specific Antigen in Patients with Prostate Cancer. In: Clinical Aspects of Prostate Cancer: Assessment of New Diagnostic and Management. Elsevier Publishing Company; 1989:233-246.
|
